Oseltamivir News and Research

RSS

WSU researcher looks for clues on link between H1N1 flu and obesity

The recent H1N1 flu pandemic was found to be particularly dangerous to obese people, and a Wayne State University researcher is looking for clues as to why.

3 Jul 2012

One of the controversial avian flu studies published in full finally

After endless debates and controversies on whether two studies that demonstrated how bird flu, also known as avian H5N1 influenza, or avian flu, should be published, one of them has appeared in the latest issue of the journal Nature in its entirety. The two studies aimed for publication in journals Nature and Science show how the bird flu virus could become transmissible from mammal-to-mammal; as humans are mammals, the same would apply to humans.

4 May 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

C&EN explains logic behind odd-sounding generic names

Oseltamivir. Esomeprazole. Trastuzumab. Where do drugs get those odd-sounding generic names? The answers are in the current issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society, which explains the logic behind the tongue-twisters.

19 Jan 2012

Tamiflu resistant flu on the rise: Study

According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.

2 Jan 2012

Plant world has great potential as a source of new medicines, says NYBG scientist

There are probably at least 500 medically useful chemicals awaiting discovery in plant species whose chemical constituents have not yet been evaluated for their potential to cure or treat disease, according to a new analysis by a New York Botanical Garden scientist who has more than 15 years of experience in collecting plants for natural-products discovery programs.

13 Dec 2011

MRSA co-infection increases risk of flu-related mortality among children

During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.

7 Nov 2011

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Something like 'Contagion' could happen for influenza

In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.

15 Sep 2011

Tamiflu resistant flu found in Newcastle, Australia

The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.

2 Sep 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection.

3 May 2011

New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan

Analysis of mutations of the 2009 pandemic influenza A(H1N1) virus by researchers at the RIKEN Omics Science Center (OSC) has revealed major genetic differences between the virus in its early phase of infection in Japan and in its peak phase. While yielding valuable clues on the genetic origins of drug resistance, the findings also pave the way toward the development of new diagnostic kits for detecting and preventing the spread of global pandemic diseases.

26 Apr 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

Biota wins U.S. drug development contract for Laninamivir

Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).

31 Mar 2011

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

Natco Pharma files ANDA with FDA for generic version of Tamiflu

Alvogen, the US-based pharmaceutical company, today announced that its India-based partner, Natco Pharma Limited, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for the generic version of Tamiflu.

9 Feb 2011

Natco Pharma submits ANDA to FDA for generic version of Tamiflu 75 mg capsules

Gilead Sciences, today announced receipt of a Paragraph IV Certification Notice Letter advising that Natco Pharma Limited submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration requesting permission to manufacture and market a generic version of Tamiflu 75 mg capsules.

7 Feb 2011